Recent study identifies CD30 expression across 17 tumor types

In a study of over 1,500 patients with nonlymphomatous malignancies, 17 different diagnoses were associated with varying degrees of CD30 expression. These data are from an interim analysis of an ongoing study.

Data were recently reported from an interim analysis of an ongoing large-scale study to characterize CD30 expression in nonlymphomatous malignancies. To date, 1,637 patients have been screened for CD30 expression. Samples were considered CD30-positive if ≥10% or ≥20% of malignant cells stained positive by immunohistochemistry (IHC) or flow cytometry, respectively. Thirty-eight patients (2%) with 17 different malignant diagnoses were CD30-positive, including 5 of 18 (28%) with mesothelioma, 6 of 64 (9%) with melanoma, 4 of 71 (6%) with triple-negative breast cancer and 9 of 173 (5%) with ovarian cancer. In CD30-positive samples, the percentage of CD30-positive malignant cells ranged from 10% to 100% and H scores ranged from 14 to 265. This study is the first systematic analysis of CD30 expression in multiple tumor types.1 For more information on CD30 expression in specific tumor types, click here.

mesothelioma, 75% Melanoma, 50% Triple-negative breast, 40% Ovarian, 12%

Reference

  1. Sharman JP, Goldschmidt JH, Burke JM, et al. CD30 expression in nonlymphomatous malignancies. Poster presented at: 48th American Society of Clinical Oncology Annual Meeting; June 1-5, 2012; Chicago, IL. Abstract 3069.

MORE UPDATES

NCCN recommends CD30-thumb

NCCN recommends CD30

The NCCN Guidelines* recommend CD30 testing for the differential diagnosis of Hodgkin and certain non-Hodgkin lymphomas...

Clinical relevance of CD30-thumb

The clinical relevance of CD30

Appropriate management of patients with lymphoma depends on an accurate diagnosis...

CD30 in NHL prognosis-thumb

CD30 in NHL prognosis

The definitive role of prevalence and intensity of CD30 in prognosis is evolving...

melanoma-thumb

Study finds CD30 in 17 cancers

In a study of over 1,500 patients with nonlymphomatous malignancies, 17 different diagnoses were associated...

burkitt-thumb

CD30 in Burkitt lymphoma

25% of Burkitt lymphoma cases express CD30. The endemic variant, African Burkitt lymphoma...

ptcl OS-thumb

CD30 and overall survival in PTCL‑NOS

A recent study found that CD30 expression is an adverse predictor of survival in peripheral T-cell lymphoma...

germ vells thumb

CD30 screening in germ cell tumors

CD30 is strongly expressed in more than 95% of embryonal carcinomas, while other germ cell tumors lack CD30...

methods thumb

Methods of detecting CD30

CD30 expression can be analyzed using immunohistochemistry on fixed tissue or flow cytometry on live cells...

*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Hodgkin’s Lymphomas V.2.2013 and Hodgkin Lymphoma V.2.2013. © National Comprehensive Cancer Network, Inc 2013. All rights reserved. Accessed September 24, 2013. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.